Publikationen

Folgende Publikationen wurden von den Ärzten unseres Hauses geleistet:

Publikationen 2015

Al Olama AA, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch GS, Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokozorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T, Lim HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Govindasami K, Guy M, Muir K, Vinuela A, Brown AA, PRACTICAL Consortium, COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative, Australian Prostate Cancer Bioresource, UK Genetic Prostate Cancer Study Collaborators, UK ProtecT Study Collaborators, Freedman M, Conti DV, Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet 2015; (e-pub ahead of print).

Amin AO, Benlloch S, Antoniou AC, Giles GG, Severi G, Neal D, Hamdy FC, Donovan JL, Muir K, Schleutker J, Henderson BE, Haiman C, Schumacher FR, Pashayan N, Pharoah PD, Ostrander EA, Stanford JL, Batra J, Clements JA, Chambers SK, Weischer M, Nordestgaard BG, Ingles SA, Sorensen KD, Orntoft TF, Park JY, Cybulski C, Maier C, Doerk T, Dickinson JL, Cannon-Albright L, Brenner H, Rebbeck TR, Zeigler-Johnson C, Habuchi T, Thibodeau SN, Cooney K, Chappuis PO, Hutter P, Kaneva RP, Foulkes WD, Zeegers MP, Lu YJ, Zhang HW, Stephenson R, Cox A, Southey MC, Spurdle AB, Fitzgerald L, Leongamornlert D, Saunders E, Tymrakiewicz M, Guy M, Dadaev T, Little SJ, Govindasami K, Sawyer E, Wilkinson R, Herkommer K, Hopper JL, Lophatonanon A, Rinckleb AE, Kote-Jarai Z, Eeles RA, Easton DF. Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev 2015; (e-pub ahead of print).

Böhm M, Maier C, Küfer R, Ropke A, Vogel W, Wieland I. Genetic Variants of DICE1/INTS6 in German Prostate Cancer Families with Linkage to 13q14. Urol Int 2015; (e-pub ahead of print).

Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. Eur Urol 2015; (e-pub ahead of print).

Draaken M, Knapp M, Pennimpede T, Schmidt JM, Ebert AK, Rosch W, Stein R, Utsch B, Hirsch K, Boemers TM, Mangold E, Heilmann S, Ludwig KU, Jenetzky E, Zwink N, Moebus S, Herrmann BG, Mattheisen M, Nothen MM, Ludwig M, Reutter H. Genome-wide association study and meta-analysis identify ISL1 as genome-wide significant susceptibility gene for bladder exstrophy. PLoS Genet 2015; 11(3):e1005024.

Ebert AK, Adamczyk K. Epispadie und Harnröhrenduplikatur [Epispadias and urethral duplication]. Urologe A 2015; 54(5):634-640.

Egbers L, Luedeke M, Rinckleb A, Kolb S, Wright JL, Maier C, Neuhouser ML, Stanford JL. Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status. Am J Epidemiol 2015; 181(9):706-713.

Hautmann RE. Editorial Comment. J Urol 2015; (e-pub ahead of print).

Hautmann RE, Abol-Enein H, Lee CT, Mansson W, Mills RD, Penson DF, Skinner EC, Studer UE, Thueroff JW, Volkmer BG. Urinary diversion: how experts divert. Urology 2015; 85(1):233-238.

Knoll N, Wiedemann AU, Schrader M, Felber J, Burkert S, Daig I, Heckhausen J. Calibrating Independence Goals and Partner Support: Couples Adjust to Functional Limitations after Tumor Surgery. Appl Psychol Health Well Being 2015; (e-pub ahead of print).

Park W, Zwink N, Rösch WH, Schmiedeke E, Stein R, Schmidt D, Noeker M, Jenetzky E, Reutter H, Ebert AK. Sexual function in adult patients with classic bladder exstrophy: A multicenter study. J Pediatr Urol 2015; (e-pub ahead of print).

Reiter R, Brosch S, Ludeke M, Fischbein E, Rinckleb A, Haase S, Schwandt A, Pickhard A, Maier C, Hogel J, Vogel W. Do orofacial clefts represent different genetic entities? Cleft Palate Craniofac J 2015; 52(1):115-120.

Schmidt S, Kunath F, Kranz J, Zengerling F, Drager DL, Kröger N, Krabbe LM, Miernik A, Borgmann H, Spek A, Meerpohl J, Dahm P, Wullich B. Der Sprachbarriere zum Trotz [Overcoming the language barrier: UroEvidence translates Cochrane abstracts]. Urologe A 2015; 54(1):76-77.

Schnoeller TJ, Steinestel J, Steinestel K, Jentzmik F, Schrader AJ. Do preoperative serum C-reactive protein levels predict the definitive pathological stage in patients with clinically localized prostate cancer? Int Urol Nephrol 2015; 47(5):765-770.

Schnoeller TJ, Steinestel J, Zengerling F, Schrader AJ, Jentzmik F. Serum 17beta-estradiol fails as a marker in identification of aggressive tumour disease in patients with localized prostate cancer. World J Urol 2015; (e-pub ahead of print).

Schnöller TJ, Zengerling F, Hirning C, Jentzmik F. Sekundäre Prävention bei Patienten mit oberflächlichem Urothelkarzinom [Secondary prevention in patients with superficial urothelial carcinoma]. Urologe A 2015; (e-pub ahead of print).

Stegeman S, Amankwah E, Klein K, O'Mara TA, Kim D, Lin HY, Permuth-Wey J, Sellers TA, Srinivasan S, Eeles R, Easton D, Kote-Jarai Z, Amin AO, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pharoah P, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Teixeira MR, PRACTICAL Consortium, Australian Prostate Cancer Bioresource, Spurdle AB, Clements JA, Park JY, Batra J. A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discov 2015; 5(4):368-379.

Steinestel J, Al Ghazal A, Arndt A, Schnoeller TJ, Schrader AJ, Moeller P, Steinestel K. The role of histologic subtype, p16(INK4a) expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma. BMC Cancer 2015; 15:220.

Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, Maier C, Cronauer MV, Steinestel K, Schrader AJ. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 2015; (e-pub ahead of print).

Weitere Originalarbeiten in Consortien:

Goulart LF, Bettella F, Sonderby IE, Schork AJ, Thompson WK, Mattingsdal M, Steen VM, Zuber V, Wang Y, Dale AM, PRACTICAL/ELLIPSE Consortium, Andreassen OA, Djurovic S. MicroRNAs enrichment in GWAS of complex human phenotypes. BMC Genomics 2015; 16(1):304.

Laitinen VH, Rantapero T, Fischer D, Vuorinen EM, Tammela TL, PRACTICAL Consortium, Wahlfors T, Schleutker J. Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer. Int J Cancer 2015; 136(10):2316-2327.

Murtola TJ, Wahlfors T, Haring A, Taari K, Stenman UH, Tammela TL, PRACTICAL Consortium, Schleutker J, Auvinen A. Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin. Eur Urol 2015; (e-pub ahead of print).

Panagiotou OA, Travis RC, Campa D, Berndt SI, Lindstrom S, Kraft P, Schumacher FR, Siddiq A, Papatheodorou SI, Stanford JL, Albanes D, Virtamo J, Weinstein SJ, Diver WR, Gapstur SM, Stevens VL, Boeing H, Bueno-de-Mesquita HB, Barricarte GA, Kaaks R, Khaw KT, Krogh V, Overvad K, Riboli E, Trichopoulos D, Giovannucci E, Stampfer M, Haiman C, Henderson B, Le Marchand L, Gaziano JM, Hunter DJ, Koutros S, Yeager M, Hoover RN, PRACTICAL Consortium, Chanock SJ, Wacholder S, Key TJ, Tsilidis KK. A genome-wide pleiotropy scan for prostate cancer risk. Eur Urol 2015; 67(4):649-657. 1

Publikationen 2014

Al Ghazal A, Schnoeller TJ, Baechle C, Steinestel J, Jentzmik F, Steffens S, Hirning C, Schrader M, Schrader AJ. Capsulotomy for treatment of compartment syndrome in patients with post extracorporeal shock wave lithotripsy renal hematomas: safe and effective, but also advisable? Urol J 2014; 11(3):1569-1574.

Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Roder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE, Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L, Cybulski C, Wokolorczyk D, Kluzniak W, Park J, Sellers T, Lin HY, Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C, Giovannucci EL, Ma J, Stampfer M, Penney KL, Mucci L, John EM, Ingles SA, Kittles RA, Murphy AB, Pandha H, Michael A, Kierzek AM, Blot W, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S, Nemesure B, Carpten J, Leske C, Wu SY, Hennis A, Kibel AS, Rybicki BA, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Batra J, Clements J, Spurdle A, Teixeira MR, Paulo P, Maia S, Slavov C, Kaneva R, Mitev V, Witte JS, Casey G, Gillanders EM, Seminara D, Riboli E, Hamdy FC, Coetzee GA, Li Q, Freedman ML, Hunter DJ, Muir K, Gronberg H, Neal DE, Southey M, Giles GG, Severi G, Breast and Prostate Cancer Cohort Consortium (BPC3), PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, COGS (Collaborative Oncological Gene-environment Study) Consortium, GAME-ON/ELLIPSE Consortium, Cook MB, Nakagawa H, Wiklund F, Kraft P, Chanock SJ, Henderson BE, Easton DF, Eeles RA, Haiman CA. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 2014; 46(10):1103-1109.

Baumunk D, Strang CM, Kropf S, Schafer M, Schrader M, Weikert S, Cash H, Breckwoldt J, Miller K, Hachenberg T, Schostak M. Impact of thoracic epidural analgesia on blood loss in radical retropubic prostatectomy. Urol Int 2014; 93(2):193-201.

Breunig C, Schrader M, Schrader AJ, Zengerling F. Organerhaltende Hodentumortherapie [Organ-sparing therapy for testicular cancer]. Urologe A 2014; 53(9):1302-1309.

Bründl J, Zengerling F, Borgmann H, Syring I. Prostataeingriffe im Rahmen der urologischen Facharztweiterbildung [Prostate surgery within residency programs in urology]. Urologe A 2014; 53(3):379-381.

Cronauer MV, Schrader MG, Schrader AJ. Re: J.A. Witjes. A Case of Abiraterone Acetate Withdrawal (Eur Urol 2013;64:517-518). Eur Urol 2014; 65(1):e10-e11.

Draaken M, Baudisch F, Timmermann B, Kuhl H, Kerick M, Proske J, Wittler L, Pennimpede T, Ebert AK, Rosch W, Stein R, Bartels E, von Lowtzow C, Boemers TM, Herms S, Gearhart JP, Lakshmanan Y, Kockum CC, Holmdahl G, Lackgren G, Nordenskjold A, Boyadjiev SA, Herrmann BG, Nothen MM, Ludwig M, Reutter H. Classic bladder exstrophy: Frequent 22q11.21 duplications and definition of a 414 kb phenocritical region. Birth Defects Res A Clin Mol Teratol 2014; 100(6):512-517.

Ebert AK, Rösch WH. Editorial Comment. J Urol 2014; 191(1):197-198.

Engel O, de Petriconi R, Volkmer BG, Gust KM, Mani J, Haferkamp A, Hautmann RE, Bartsch G. The feasibility of ureteral tissue engineering using autologous veins: an orthotopic animal model with long term results. J Negat Results Biomed 2014; 13(1):17.

Hautmann RE. Editorial comment. Urology 2014; 84(4):813.

Hautmann RE, Herr HW, Pruthi RS, Aron M. Robotic radical cystectomy-is the diversion the achilles' heel? J Urol 2014; 192(6):1601-1603.

Hegele A, Skrobek L, Schrader AJ. ASCO, ESMO, AUA, EAU, DGU - Update Uroonkologie - Was war klinisch relevant auf den Kongressen 2013? [Update Urooncology: News with clinical relevance from major scientific meetings 2013]. Aktuelle Urol 2014; 45(1):21-32.

Jentzmik F, Schnoeller TJ, Cronauer MV, Steinestel J, Steffens S, Zengerling F, Al Ghazal A, Schrader MG, Steinestel K, Schrader AJ. Corpulence is the crucial factor: association of testosterone and/or obesity with prostate cancer stage. Int J Urol 2014; 21(10):980-986.

Knoll N, Wiedemann AU, Schultze M, Schrader M, Heckhausen J. Prostate cancer patients gradually advance goals for rehabilitation after radical prostatectomy: applying a lines-of-defense model to rehabilitation. Psychol Aging 2014; 29(4):787-792.

Kranz J, Kunath F, Borgmann H, Dräger DL, Krabbe LM, Kröger N, Otto W, Spek A, Zengerling F, Wullich B, Miernik A. „UroEvidence" – Zentrum für evidenzbasierte Medizin der DGU ["UroEvidence" - Centre for knowledge translation of the DGU (German Society of Urology). Summarizing, analysing and making current knowledge available]. Urologe A 2014; 53(1):83-86.

Lee RK, Abol-Enein H, Artibani W, Bochner B, Dalbagni G, Daneshmand S, Fradet Y, Hautmann RE, Lee CT, Lerner SP, Pycha A, Sievert KD, Stenzl A, Thalmann G, Shariat SF. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int 2014; 113(1):11-23.

Magheli A, Busch J, Leva N, Schrader M, Deger S, Miller K, Lein M. Comparison of surgical technique (open vs. laparoscopic) on pathological and long term functional outcomes following radical prostatectomy. BMC Urol 2014; 14:18.

Maier C, Herkommer K, Luedeke M, Rinckleb A, Schrader M, Vogel W. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations. Prostate 2014; 74(14):1444-1451.

Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology 2014; 83(4):863-867.

Reutter H, Draaken M, Pennimpede T, Wittler L, Brockschmidt FF, Ebert AK, Bartels E, Rosch W, Boemers TM, Hirsch K, Schmiedeke E, Meesters C, Becker T, Stein R, Utsch B, Mangold E, Nordenskjold A, Barker G, Kockum CC, Zwink N, Holmdahl G, Lackgren G, Jenetzky E, Feitz WF, Marcelis C, Wijers CH, Van Rooij IA, Gearhart JP, Herrmann BG, Ludwig M, Boyadjiev SA, Nothen MM, Mattheisen M. Genome-wide association study and mouse expression data identify a highly conserved 32 kb intergenic region between WNT3 and WNT9b as possible susceptibility locus for isolated classic exstrophy of the bladder. Hum Mol Genet 2014; 23(20):5536-5544.

Roos FC, Steffens S, Junker K, Janssen M, Becker F, Wegener G, Brenner W, Steinestel J, Schnoeller TJ, Schrader M, Hofmann R, Thuroff JW, Kuczyk MA, Wunderlich H, Siemer S, Hartmann A, Stöckle M, Schrader AJ. Survival advantage of partial over radical nephrectomy in patients presenting with localized renal cell carcinoma. BMC Cancer 2014; 14:372.

Sathe A, Guerth F, Cronauer MV, Heck MM, Thalgott M, Gschwend JE, Retz M, Nawroth R. Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Br J Cancer 2014; 111(11):2103-2113.

Saunders EJ, Dadaev T, Leongamornlert DA, Jugurnauth-Little S, Tymrakiewicz M, Wiklund F, Al Olama AA, Benlloch S, Neal DE, Hamdy FC, Donovan JL, Giles GG, Severi G, Gronberg H, Aly M, Haiman CA, Schumacher F, Henderson BE, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock S, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Nordestgaard BG, Canzian F, Campa D, Riboli E, Key TJ, Travis RC, Ingles SA, John EM, Hayes RB, Pharoah P, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Clements JA, Teixeira MR, Xu J, Mikropoulos C, Goh C, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative, UK Genetic Prostate Cancer Study Collaborators, UK ProtecT Study Collaborators, PRACTICAL Consortium, Easton DF, Muir K, Eeles RA, Kote-Jarai Z. Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. PLoS Genet 2014; 10(2):e1004129.

Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV. Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone. Eur Urol 2014; 65(1):30-36.

Schrader AJ, Schrader MG, Cronauer MV. Re: Christoph A. von Klot, Markus A. Kuczyk, Axel S. Merseburger. No Androgen Withdrawal Syndrome for Enzalutamide: A Report of Disease Dynamics in the Postchemotherapy Setting (Eur Urol 65:258-259): Enzalutamide Withdrawal Syndrome: Fact or Fiction?http://www.ncbi.nlm.nih.gov/pubmed/24210913 Eur Urol 2014; 65(2):e22-23. 

Schrader AJ, Seseke S, Keil C, Herrmann E, Goebell PJ, Weikert S, Steffens S, Bergmann L, Roigas J, Steiner T. Temsirolimus in Daily Use: Results of a Prospective Multicentre Noninterventional Study of Patients with Metastatic Kidney Cancer. Eur Urol 2013;

Steffens S, Janssen M, Roos FC, Becker F, Steinestel J, Abbas M, Steinestel K, Wegener G, Siemer S, Thuroff JW, Hofmann R, Stockle M, Schrader M, Hartmann A, Hasenfus A, Kuczyk MA, Junker K, Schrader AJ. The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma. Hum Pathol 2014; 45(12):2411-2416.

Steffens S, Junker K, Roos FC, Janssen M, Becker F, Henn D, Wegener G, Siemer S, Hofmann R, Schrader M, Stöckle M, Thüroff JW, Hartmann A, Kuczyk MA, Schrader AJ. Small renal cell carcinomas - How dangerous are they really? Results of a large multicenter study. Eur J Cancer 2013;

Steffens S, Roos FC, Janssen M, Becker F, Steinestel J, Abbas M, Steinestel K, Wegener G, Siemer S, Thuroff JW, Hofmann R, Stockle M, Schrader M, Hartmann A, Junker K, Kuczyk MA, Schrader AJ. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size. Virchows Arch 2014; 465(4):439-444.

Steffens S, Schrader AJ, Lehmann R, Eggers H, Ising S, Pfister D, Riechert-Mühe N, Leitenberger A, Heidenreich A, Thon W, Merseburger AS, Kuczyk MA. Blickdiagnose bei der transurethralen Resektion von Harnblasentumoren [Visual diagnosis while performing transurethral resection of bladder tumors : Power or myth?]. Urologe A 2014; 53(11):1639-1643.

Steinestel J, Schrader AJ, Luedeke M. Resistance to androgen-pathway drugs in prostate cancer. N Engl J Med 2014; 371(23):2234.

Steinestel K, Brüderlein S, Lennerz JK, Steinestel J, Kraft K, Propper C, Meineke V, Möller P. Expression and Y435-phosphorylation of Abelson interactor 1 (Abi1) promotes tumour cell adhesion, extracellular matrix degradation and invasion by colorectal carcinoma cells. Mol Cancer 2014; 13:145.

Steinestel K, Eder S, Schrader AJ, Steinestel J. Clinical significance of epithelial-mesenchymal transition. Clin Transl Med 2014; 3:17.

Streicher W, Luedeke M, Azoitei A, Zengerling F, Herweg A, Genze F, Schrader MG, Schrader AJ, Cronauer MV. Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARDeltaLBD-signalling in human prostate cancer cells. PLoS One 2014; 9(6):e98566.

Teerlink CC, Thibodeau SN, McDonnell SK, Schaid DJ, Rinckleb A, Maier C, Vogel W, Cancel-Tassin G, Egrot C, Cussenot O, Foulkes WD, Giles GG, Hopper JL, Severi G, Eeles R, Easton D, Kote-Jarai Z, Guy M, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Fitzgerald LM, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Wahlfors T, Tammela T, Schleutker J, Wiklund F, Gronberg H, Emanuelsson M, Carpten J, Bailey-Wilson J, Whittemore AS, Oakley-Girvan I, Hsieh CL, Catalona WJ, Zheng SL, Jin G, Lu L, Xu J, Camp NJ, Cannon-Albright LA. Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Hum Genet 2013; (e-pub ahead of print)

Xylinas E, Cha EK, Khani F, Kluth LA, Rieken M, Volkmer BG, Hautmann R, Küfer R, Chen YT, Zerbib M, Rubin MA, Scherr DS, Shariat SF, Robinson BD. Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. J Urol 2013; (e-pub ahead of print)

Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Küfer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, Shariat SF. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol 2014; 40(1):121-127.

Zengerling F, Hartmann M, Heidenreich A, Krege S, Albers P, Karl A, Weissbach L, Wagner W, Bedke J, Retz M, Schmelz HU, Kliesch S, Kuczyk M, Winter E, Pottek T, Dieckmann KP, Schrader AJ, Schrader M. German second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practice. Oncol Rep 2014; 31(6):2477-2481.

Zengerling F, Krege S, Schrader AJ, Schrader M. Nationales Zweitmeinungsnetzwerk Hodentumoren - ein System zum Evidenztransfer! [National second opinion network for testicular cancer patients - transferring guidelines into practice!]. Aktuelle Urol 2014; 45(6):454-456.

Zengerling F, Müller J, Krege S, Schrader M. Diagnostik und Therapie seminomatöser Hodentumoren [Diagnostics and treatment of seminomatous germ cell tumors]. Urologe A 2014; 53(4):563-574.

Publikationen 2013

Al Ghazal A, Steffens S, Steinestel J, Lehmann R, Schnoeller TJ, Schulte-Hostede A, Wegener G, Jentzmik F, Schrader M, Kuczyk MA, Schrader AJ. Elevated C-reactive protein values predict nodal metastasis in patients with penile cancer. BMC Urol 2013; 13(1):53.

 

Amin AO, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC, Cox DG, Canzian F, Riboli E, Key TJ, Andriole G, Albanes D, Hayes RB, Schleutker J, Auvinen A, Tammela TL, Weischer M, Stanford JL, Ostrander EA, Cybulski C, Lubinski J, Thibodeau SN, Schaid DJ, Sorensen KD, Batra J, Clements JA, Chambers S, Aitken J, Gardiner RA, Maier C, Vogel W, Dork T, Brenner H, Habuchi T, Ingles S, John EM, Dickinson JL, Cannon-Albright L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, Park JY, Cooney KA, Muir KR, Leongamornlert DA, Saunders E, Tymrakiewicz M, Mahmud N, Guy M, Govindasami K, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English D, Virtamo J, Le Marchand L, Campa D, Kaaks R, Lindstrom S, Diver WR, Gapstur S, Yeager M, Cox A, Stern MC, Corral R, Aly M, Isaacs W, Adolfsson J, Xu J, Zheng SL, Wahlfors T, Taari K, Kujala P, Klarskov P, Nordestgaard BG, Roder MA, Frikke-Schmidt R, Bojesen SE, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Rinckleb A, Luedeke M, Herkommer K, Meyer A, Serth J, Marthick JR, Patterson B, Wokolorczyk D, Spurdle A, Lose F, McDonnell SK, Joshi AD, Shahabi A, Pinto P, Santos J, Ray A, Sellers TA, Lin HY, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V, Chanock S, Gronberg H, Haiman CA, Kraft P, Easton DF, Eeles RA. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet 2013; 22(2):408-415.

 

Baumunk D, Reunkoff R, Kushner J, Baumunk A, Kempkensteffen C, Steiner U, Weikert S, Moser L, Schrader M, Höcht S, Wiegel T, Miller K, Schostak M. Interdisciplinary decision making in prostate cancer therapy - 5-years' time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charite Berlin. BMC Med Inform Decis Mak 2013; 13:83.

 

Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Classen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germa L, Jr., Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LH, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 2013; 24(4):878-888.

 

Blacha C, Schmid MM, Gahr M, Freudenmann RW, Plener PL, Finter F, Connemann BJ, Schönfeldt-Lecuona C. Self-inflicted testicular amputation in first lysergic acid diethylamide use. J Addict Med 2013; 7(1):83-84.

 

Damjanoski I, Müller J, Schnöller TJ, Küfer R, Rinnab L. Histopathologische Befundberichte von Prostatastanzbiopsien [Histopathology reports of findings of prostate needle biopsies : Indiviaual treatment.]. Urologe A 2013; 52(2):226-239.

 

Ebert AK, Rösch W. Paediatric urology: Is osteotomy necessary for primary exstrophy closure? Nat Rev Urol 2013; 10(11):625-626.

 

Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Roder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC, Kote-Jarai Z, Easton DF. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013; 45(4):385-391.

 

Eggers H, Kuczyk MA, Schrader AJ, Steffens S. Der Einfluss von Adipositas auf urologische Tumorerkrankungen [Influence of obesity on urological malignancies]. Urologe A 2013; 52(9):1270-1275.

 

Eggers H, Seidel C, Schrader AJ, Lehmann R, Wegener G, Kuczyk MA, Steffens S. Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder. Med Oncol 2013; 30(4):705.

 

Hautmann RE, Abol-Enein H, Davidsson T, Gudjonsson S, Hautmann SH, Holm HV, Lee CT, Liedberg F, Madersbacher S, Manoharan M, Mansson W, Mills RD, Penson DF, Skinner EC, Stein R, Studer UE, Thueroff JW, Turner WH, Volkmer BG, Xu A. ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary Diversion. Eur Urol 2013; 63(1):67-80.

 

Köhler A, Eggers H, Kuczyk MA, Schrader AJ, Steffens S. Stellenwert des Serum-CRP-Wertes zur Einschätzung von Prognose und therapeutischem Ansprechen urologischer Malignome [Utility of the Serum CRP Value for Assessing the Prognosis and Therapeutic Response of Urological Malignancies]. Aktuelle Urol 2013; 44(6):452-455. 

Kote-Jarai Z, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Dadaev T, Jugurnauth-Little S, Ross-Adams H, Al Olama AA, Benlloch S, Halim S, Russell R, Dunning AM, Luccarini C, Dennis J, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock S, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah P, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle A, Clements JA, Teixeira MR, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dicks E, Baynes C, Conroy D, Bojesen SE, Kaaks R, Vincent D, Bacot F, Tessier DC, Easton DF, Eeles RA. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet 2013; 22(12):2520-2528.

Mueller J, Schrader AJ, Schrader M, Schnoeller T, Jentzmik F. Management of muscle-invasive bladder cancer. Minerva Urol Nefrol 2013; 65(4):235-248.

Rink M, Park K, Volkmer BG, Xylinas E, Hansen J, Cha EK, Robinson BD, Hautmann R, Küfer R, Engel O, Chun FK, Dahlem R, Rubin MA, Shariat SF, Mosquera JM. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. Urol Oncol 2013; 31(8):1716-1724.

 

Schnoeller T, Jentzmik F, Rinnab L, Cronauer MV, Damjanoski I, Zengerling F, Ghazal AA, Schrader M, Schrader AJ. Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. World J Urol 2013; 31(2):253-259.

 

Schnoeller TJ, de Petriconi R, Hefty R, Jentzmik F, Al Ghazal A, Steinestel J, Mueller J, Zengerling F, Schrader M, Schrader AJ. Anwendung von Surgisis® zur Optimierung und Vereinfachung der Nierenteilresektion bei größeren renalen Neoplasmen [The use of Surgisis(R) optimizes and simplifies partial nephrectomy for large renal tumors.]. Urologe A 2013; 52(2):246-251. .

 

Schrader AJ, Schrader MG, Cronauer MV. Words of wisdom. Re: androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Eur Urol 2013; 64(1):169-170.

Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PC, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 2013; 45(12):1428-1430.

Steffens S, Al Ghazal A, Steinestel J, Lehmann R, Wegener G, Schnoeller TJ, Cronauer MV, Jentzmik F, Schrader M, Kuczyk MA, Schrader AJ. High CRP values predict poor survival in patients with penile cancer. BMC Cancer 2013; 13:223.

 

Steffens S, Ringe KI, Schroeer K, Lehmann R, Rustemeier J, Wegener G, Schrader M, Hofmann R, Kuczyk MA, Schrader AJ. Does overweight influence the prognosis of renal cell carcinoma? Results of a multicenter study. Int J Urol 2013; 20(6):585-592.

 

Stein B, Schrader AJ, Wegener G, Seidel C, Kuczyk MA, Steffens S. Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma. BMC Cancer 2013; 13:101.

 

Steinestel J, Cronauer MV, Müller J, Al Ghazal A, Skowronek P, Arndt A, Kraft K, Schrader M, Schrader AJ, Steinestel K. Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection. PLoS One 2013; 8(5):e65189.

 

Steinestel K, Gläsle F, Brüderlein S, Steinestel J, Pröpper C, Möller P. Abelson interactor 1 (Abi1) im kolorektalen Karzinom: Von der synaptischen Plastizität zur Tumorzellmigration [Abelson interactor 1 (Abi1) in colorectal cancer: From synaptic plasticity to tumor cell migration]. Pathologe 2013; 34(Suppl 2):189-194.

 

Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, Cannon-Albright LA, Teerlink CC, Camp NJ, Johnson AM, Zuhlke KA, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Maier C, Luedeke M, Vogel W, Schleutker J, Wahlfors T, Tammela T, Schaid D, McDonnell SK, Derycke MS, Cancel-Tassin G, Cussenot O, Wiklund F, Gronberg H, Eeles R, Easton D, Kote-Jarai Z, Whittemore AS, Hsieh CL, Giles GG, Hopper JL, Severi G, Catalona WJ, Mandal D, Ledet E, Foulkes WD, Hamel N, Mahle L, Moller P, Powell I, Bailey-Wilson JE, Carpten JD, Seminara D, Cooney KA, Isaacs WB. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 2013; 132(1):5-14.

 

Zengerling F, Müller J, Schrader AJ, Schrader M. Seminom klinisches Stadium I - Neuer Therapiestandard Surveillance? [Clinical stage I seminoma - Is surveillance a new therapy standard?]. Urologe A 2013; 52(9):1265-1269.

 

Zengerling F, Schrader AJ, Mohr A, Schrader M. Nationales Zweitmeinungsnetzwerk testikuläre Keimzelltumoren [National second-opinion network for testicular cancer patients. Results of a user survey]. Urologe A 2013; 52(9):1290-1295.

 

Weitere Originalarbeiten in Consortien:
Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Köbel M, PRACTICAL Consortium, et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun 2013; 4:1628.

 

Yu OH, Foulkes WD, Dastani Z, Martin RM, Eeles R, PRACTICAL Consortium, CRUK GWAS Investigators, Richards JB. An assessment of the shared allelic architecture between type II diabetes and prostate cancer. Cancer Epidemiol Biomarkers Prev 2013; 22(8):1473-1475.

Publikationen 2012

Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gössele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, Scholl C. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med 2012; 209(4):697-711.

Bailey-Wilson JE, Childs EJ, Cropp CD, Schaid DJ, Xu J, Camp NJ, Cannon-Albright LA, Farnham JM, George A, Powell I, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Guy M, Edwards S, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Stanford JL, Karyadi DM, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Thibodeau SN, McDonnell SK, Hebbring S, Lange EM, Cooney KA, Tammela TL, Schleutker J, Maier C, Borchum S, Hoegel J, Gronberg H, Wiklund F, Emanuelsson M, Cancel-Tassin G, Valeri A, Cussenot O, Isaacs WB. Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. BMC Med Genet 2012; 13(1):46.

Ballouhey Q, Thoulouzan M, Lunardi P, Bellec L, Huyghe E, Plante P, de Petriconi R, Soulié M. Étude prospective chez 100 patients des résultats de la technique d'anastomose urétéro-iléale en double cheminée dans la néovessie de Hautmann [Prospective study of the results of ureterointestinal anastomosis in 100 patients after the Hautmann ileal neobladder with double chimney]. Prog Urol 2012; 22(5):255-260.

Bottke D, Bartkowiak D, Schrader M, Wiegel T. Radiotherapy after radical prostatectomy: immediate or early delayed? Strahlenther Onkol 2012; 188(12):1096-1101.

Busch J, Magheli A, Erber B, Friedersdorff F, Hoffmann I, Kempkensteffen C, Weikert S, Miller K, Schrader M, Hinz S. Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer--a single center analysis. BMC Urol 2012; 1215.

Chromecki TF, Mauermann J, Cha EK, Svatek RS, Fajkovic H, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Novara G, Fritsche HM, Ficarra V, Stief CG, Dinney CP, Skinner E, Pummer K, Fradet Y, Shariat SF. Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. World J Urol 2012; 30(6):753-759.

Cronauer MV, Culig Z. Molecular aspects of prostate cancer. World J Urol 2012; 30(3):277-278.

Erber B, Schrader M, Miller K, Schostak M, Baumunk D, Lingnau A, Schrader AJ, Jentzmik F. Morbidity and Quality of Life in Bladder Cancer Patients following Cystectomy and Urinary Diversion: A Single-Institution Comparison of Ileal Conduit versus Orthotopic Neobladder. ISRN Urol 2012; 2012:342796.

Gloesenkamp C, Nitzsche B, Lim AR, Normant E, Vosburgh E, Schrader M, Ocker M, Scherubl H, Höpfner M. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. Int J Oncol 2012; 40(5):1659-1667.

Hafner S, Ehrmann U, Jentzmik F, Klingler W, Georgieff M, Froeba G. Fulminant rhabdomyolysis after prolonged radical prostatectomy managed with continuous veno-venous haemodialysis, regional citrate anticoagulation, and a polysulphone high-flux filter. Br J Anaesth 2012; 108(4):702-703.

Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant or Adjuvant Therapy: Long-Term Results in 1100 Patients. Eur Urol 2012; 61(5):1039-1047.

Hegele A, Skrobek L, Schrader AJ. ASCO, ESMO, AUA, DGU - Update Uro-Onkologie: Was gab's Neues auf den Kongressen 2011? [Update uro-oncology: scientific meetings 2011]. Aktuelle Urol 2012; 43(1):13-27.

Isachenko V, Maettner R, Petrunkina AM, Sterzik K, Mallmann P, Rahimi G, Sanchez R, Risopatron J, Damjanoski I, Isachenko E. Vitrification of Human ICSI/IVF Spermatozoa Without Cryoprotectants: New Capillary Technology. J Androl 2012; 33(3):462-468.

Isachenko V, Mallmann P, Petrunkina AM, Rahimi G, Nawroth F, Hancke K, Felberbaum R, Genze F, Damjanoski I, Isachenko E. Comparison of In Vitro- and Chorioallantoic Membrane (CAM)-Culture Systems for Cryopreserved Medulla-Contained Human Ovarian Tissue. PLoS One 2012; 7(3):e32549.

Jain G, Cronauer MV, Schrader M, Möller P, Marienfeld RB. NF-kappaB signaling in prostate cancer: A promising therapeutic target? World J Urol 2012; 30(3):303-310.

Jain G, Voogdt C, Tobias A, Spindler KD, Möller P, Cronauer MV, Marienfeld RB. I-kappaB-kinases modulate the activity of the androgen receptor in prostate cancer cell lines. Neoplasia 2012; 14(3):178-189.

Jentzmik F, Krause H, Reichelt U, Schrader AJ, Schrader M, Baumunk D, Cash H, Miller K, Schostak M. GSTP1 CpG island hypermethylation for DNA-based detection of occult tumor cells in surgical margins after radical prostatectomy. World J Urol 2012; 30(4):541-546.

Jentzmik F, Schrader AJ, de Petriconi R, Hefty R, Mueller J, Doetterl J, Eickhoff A, Schrader M. The ileal neobladder in female patients with bladder cancer: long-term clinical, functional, and oncological outcome. World J Urol 2012; 30(6):733-739.

Jentzmik F, Schrader M, de Petriconi R, Hefty R, Doetterl J, Eickhoff A, Schrader AJ. Zystektomie mit Anlage einer Ileumneoblase bei einer über 70-jährigen Frau [Radical cystectomy and ileal neobladder reconstruction in elderly female patients over 70 years old: morbidity, functional and oncological long-term results]. Urologe A 2012; 51(10):1419-1423.

Jin G, Lu L, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Cannon-Albright LA, Camp NJ, Teerlink CC, Fitzgerald LM, Stanford JL, Wiley KE, Isaacs SD, Walsh PC, Foulkes WD, Giles GG, Hopper JL, Severi G, Eeles R, Easton D, Kote-Jarai Z, Guy M, Rinckleb A, Maier C, Vogel W, Cancel-Tassin G, Egrot C, Cussenot O, Thibodeau SN, McDonnell SK, Schaid DJ, Wiklund F, Gronberg H, Emanuelsson M, Whittemore AS, Oakley-Girvan I, Hsieh CL, Wahlfors T, Tammela T, Schleutker J, Catalona WJ, Zheng SL, Ostrander EA, Isaacs WB, Xu J. Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 2012; 131(7):1095-1103.

Kälble T, Hofmann I, Thüroff JW, Stein R, Hautmann R, Riedmiller H, Vergho D, Hertle L, Wülfing C, Truss M, Roth S, von Rundstedt FC, Albers P, Gschwend J, Herkommer K, Humke U, Spahn M, Bader P, Steffens J, Harzmann R, Stief CG, Karl A, Müller SC, Waldner M, Noldus J, Kleinschmidt K, Alken P, Kopper B, Fisch M, Lampel A, Stenzel A, Fichtner J, Flath B, Rübben H, Juenemann KP, Hautmann S, Knipper A, Leusmann D, Strohmaier W, Thon WF, Miller S, Weingärtner K, Schilling A, Piechota H, Becht JE, Schwaibold H, Bub P, Conrad S, Wenderoth U, Merkle W, Rösch W, Otto T, Ulshöfer B, Westenfelder M. Sekundärmalignome in Harnableitungen [Secondary malignancies in urinary diversions]. Urologe A 2012; 51(4):500-506.

Laschak M, Spindler KD, Schrader AJ, Hessenauer A, Streicher W, Schrader M, Cronauer MV. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cacner cells. BMC Cancer 2012; 12(1):130.

Lu L, Cancel-Tassin G, Valeri A, Cussenot O, Lange EM, Cooney KA, Farnham JM, Camp NJ, Cannon-Albright LA, Tammela TL, Schleutker J, Hoegel J, Herkommer K, Maier C, Vogel W, Wiklund F, Emanuelsson M, Gronberg H, Wiley KE, Isaacs SD, Walsh PC, Helfand BT, Kan D, Catalona WJ, Stanford JL, Fitzgerald LM, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Thibodeau SN, McDonnell SK, Hebbring S, Schaid DJ, Whittemore AS, Oakley-Girvan I, Hsieh CL, Powell I, Bailey-Wilson JE, Cropp CD, Simpson C, Carpten JD, Seminara D, Zheng SL, Xu J, Giles GG, Severi G, Hopper JL, English DR, Foulkes WD, Maehle L, Moller P, Badzioch MD, Edwards S, Guy M, Eeles R, Easton D, Isaacs WB. Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. Prostate 2012; 72(4):410-426.

Luedeke M, Coinac I, Linnert CM, Bogdanova N, Rinckleb AE, Schrader M, Vogel W, Hoegel J, Meyer A, Dork T, Maier C. Prostate Cancer Risk Is not Altered by TP53AIP1 Germline Mutations in a German Case-Control Series. PLoS One 2012; 7(3):e34128.

Mueller J, Schrader AJ, Schnoeller T, Zengerling F, Damjanoski I, Al Ghazal A, Schrader M, Jentzmik F. The retrourethral transobturator sling suspension in the treatment of male urinary stress incontinence: results of a single institution experience. ISRN Urol 2012; 2012:304205.

Müller J, Schrader M, Schrader AJ, Höpfner M, Zengerling F. Stellenwert der Positronenemissionstomographie bei urologischen Tumoren: Mehr Schein als Sein? [Value of positron emission tomography in urological neoplasms : More form than substance?]. Urologe A 2012; 51(3):331-340.

Nitzsche B, Gloesenkamp C, Schrader M, Hoffmann B, Zengerling F, Balabanov S, Honecker F, Höpfner M. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. Br J Cancer 2012; 107(11):1853-1863.

Rinckleb AE, Surowy HM, Luedeke M, Varga D, Schrader M, Hoegel J, Vogel W, Maier C. The prostate cancer risk locus at 10q11 is associated with DNA repair capacity. DNA Repair (Amst) 2012; 11(8):693-701.

Rinnab L, Schrader AJ, Schrader M, Zengerling F. Männliche Sexualität im Alter [Male sexuality in the elderly]. Urologe A 2012; 51(10):1399-1413.

Rogenhofer S, Zengerling F, Schrader M, Müller SC. Leitlinien: Realität und Qualität [Guidelines: reality and quality]. Urologe A 2012; 51(8):1074-1077.

Schnoeller TJ, Ghazal AA, Jentzmik F, Mueller J, Schrader M, Schrader AJ. Palliativmedizin und medikamentöse Therapie in der Sterbephase [Palliative Care and Medicamentous Therapy during the Final Episode of Life]. Aktuelle Urol 2012; 43(6):403-408.

Schrader AJ, Steffens S. Renal Cell Carcinoma Update: News from the AUA, EAU, and ASCO Annual Meetings 2011. ISRN Urol 2012; 2012:748235.

Schrader AJ, Steffens S, Schnoeller TJ, Schrader M, Kuczyk MA. Neoadjuvant therapy of renal cell carcinoma: A novel treatment option in the era of targeted therapy? Int J Urol 2012; 19(10):903-907.

Sell K, Barth PJ, Moll R, Thomas MA, Zimmer N, Oplesch E, Gudo M, Schrader M, Hofmann R, Schrader AJ. Localization of FOXP3-positive cells in renal cell carcinoma. Tumour Biol 2012; 33(2):507-513.

Steffens S, Janssen M, Roos FC, Becker F, Schumacher S, Seidel C, Wegener G, Thüroff JW, Hofmann R, Stöckle M, Siemer S, Schrader M, Hartmann A, Kuczyk MA, Junker K, Schrader AJ. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma - A multicentre study. Eur J Cancer 2012; Eur J Cancer 2012; 48(15):2347-2352.

Steffens S, Kohler A, Rudolph R, Eggers H, Seidel C, Janssen M, Wegener G, Schrader M, Kuczyk MA, Schrader AJ. Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer 2012; 12399.

Steffens S, Schrader AJ, Vetter G, Eggers H, Blasig H, Becker J, Kuczyk MA, Serth J. Fibronectin 1 protein expression in clear cell renal cell carcinoma. Oncol Lett 2012; 3(4):787-790.

Streicher W, Zengerling F, Laschak M, Weidemann W, Höpfner M, Schrader AJ, Jentzmik F, Schrader M, Cronauer MV. AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells. World J Urol 2012; 30(3):333-339.

Winter C, Pfister D, Busch J, Bingol C, Ranft U, Schrader M, Dieckmann KP, Heidenreich A, Albers P. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol 2012; 61(2):403-409.

Zengerling F, Schrader AJ, Cronauer MV, Stemann H, Schrader M, Rinnab L. The "Aging Males' Symptoms" Scale (AMS): predictive value for lowered circulating androgens. Aging Male 2012; 15(4):253-257.

Zengerling F, Schrader AJ, Schrader M, Jentzmik F. Diagnostischer Stellenwert der Cholin-PET / CT bei Patienten mit Prostatakarzinom [Diagnostic relevance of choline-PET / CT in patients with prostate cancer]. Aktuelle Urol 2012; 43(1):49-54.

 

Zengerling F, Streicher W, Schrader AJ, Schrader M, Nitzsche B, Cronauer MV, Hopfner M. Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells. Int J Mol Sci 2012; 13(9):11530-11542.

Publikationen 2011

Azoitei N, Kleger A, Schoo N, Thal DR, Brunner C, Pusapati GV, Filatova A, Genze F, Möller P, Acker T, Kuefer R, van Lint J, Baust H, Adler G, Seufferlein T. Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation. Neuro Oncol 2011; 13(7):710-724.

Braun M, Scheble VJ, Menon R, Scharf G, Wilbertz T, Petersen K, Beschorner C, Reischl M, Kuefer R, Schilling D, Stenzl A, Kristiansen G, Rubin MA, Fend F, Perner S. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology 2011; 58(7):1028-1036.

Gschwend JE, Albers P, Schrader M. Prostatakarzinomzentren und Hodentumorzweitmeinungszentren: Erfolgsmodelle uroonkologischer Leitfunktionen [Certified prostate cancer centers and second opinion centers for testicular cancer: successful models of uro-oncology cancer care]. Urologe A 2011; 50(8):921-927.

Hautmann RE. Words of Wisdom. Re: how close are we to knowing whether orthotopic bladder replacement surgery is the new gold standard? Evidence from a systematic review update. Eur Urol 2011; 59(2):303-304.

Hautmann RE, de Petriconi RC, Volkmer BG. 25 years of experience with 1,000 neobladders: long-term complications. J Urol 2011; 185(6):2207-2212.

Hautmann RE, Hautmann SH, Hautmann O. Complications associated with urinary diversion. Nat Rev Urol 2011; 8(12):667-677.

Isachenko V, Maettner R, Petrunkina AM, Mallmann P, Rahimi G, Sterzik K, Sanchez R, Risopatron J, Damjanoski I, Isachenko E. Cryoprotectant-free vitrification of human spermatozoa in large (up to 0.5 mL) volume: a novel technology. Clin Lab 2011; 57(9-10):643-650.

Isachenko V, Nawroth F, Rahimi G, Mallmann P, Hancke K, Genze F, Schrader M, Cronauer M, Damjanoski I, Felberbaum R, Isachenko E. Die vaskularisierte Chorioallantoismembran (CAM): Ein Kultursystem für kryokonserviertes menschliches Ovarialgewebe als  Alternative zur Xenotransplantation. Geburtsh Frauenheilk 2011; 71:862-868.

Jentzmik F, Schrader AJ, Schrader M. Re: Beat Roth, Frederic D. Birkhauser, Pascal Zehnder, et al. Readaptation of the peritoneum following extended pelvic lymphadenectomy and cystectomy has a significant beneficial impact on early postoperative recovery and complications: results of a prospective randomized trial. Eur Urol 2011;59:204-10. Eur Urol 2011; 59(4):e17-e18.

Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, Campa D, Riboli E, Key T, Gronberg H, Hunter DJ, Kraft P, Thun MJ, Ingles S, Chanock S, Albanes D, Hayes RB, Neal DE, Hamdy FC, Donovan JL, Pharoah P, Schumacher F, Henderson BE, Stanford JL, Ostrander EA, Sorensen KD, Dork T, Andriole G, Dickinson JL, Cybulski C, Lubinski J, Spurdle A, Clements JA, Chambers S, Aitken J, Gardiner RA, Thibodeau SN, Schaid D, John EM, Maier C, Vogel W, Cooney KA, Park JY, Cannon-Albright L, Brenner H, Habuchi T, Zhang HW, Lu YJ, Kaneva R, Muir K, Benlloch S, Leongamornlert DA, Saunders EJ, Tymrakiewicz M, Mahmud N, Guy M, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English DR, Wahlfors T, Tammela TL, Klarskov P, Nordestgaard BG, Roder MA, Tybjaerg-Hansen A, Bojesen SE, Travis R, Canzian F, Kaaks R, Wiklund F, Aly M, Lindstrom S, Diver WR, Gapstur S, Stern MC, Corral R, Virtamo J, Cox A, Haiman CA, Le Marchand L, Fitzgerald L, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Meyer A, Serth J, Yeager M, Berndt SI, Marthick JR, Patterson B, Wokolorczyk D, Batra J, Lose F, McDonnell SK, Joshi AD, Shahabi A, Rinckleb AE, Ray A, Sellers TA, Lin HY, Stephenson RA, Farnham J, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V, Easton DF, Eeles RA. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011; 43(8):785-791.

Meilinger M, Durner L, von Ostau N. Attraktive Lehre und Ausbildung - gesicherte Zukunft der Urologie: Das Programm der urologischen Assistentenvereinigung GeSRU e.V. [Attractive teaching and training - secure future for urology: the program of the German Society of Residents in Urology (GeSRU)]. Urologe A 2011; 50(5):605-606.

Meilinger M, von Ostau N, Schöne S. 10 Jahre GeSRU-Assistenten-Workshop in Garminsch-Partenkirchen [10 years of GeSRU (German Society of Residents in Urology) assistant workshops in Garmisch-Partenkirchen]. Urologe A 2011; 50(9):1168.

Müller J, Schrader AJ, Jentzmik F, Schrader M. Beurteilung von Residualtumoren nach Systemtherapie des metastasierten Seminoms: (18)F-2-Fluor-2-Deoxy-D-Glucose-Positronenemissionstomographie - Metaanalyse zur diagnostischen Wertigkeit [Assessment of residual tumours after systemic treatment of metastatic seminoma: (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value]. Urologe A 2011; 50(3):322-327.

Schnoeller TJ, de Petriconi R, Hefty R, Jentzmik F, Waalkes S, Zengerling F, Schrader M, Schrader AJ. Partial nephrectomy using porcine small intestinal submucosa. World J Surg Oncol 2011; 9:126.

Schnöller TJ, Jentzmik F, Al Ghazal A, Zengerling F, de Petriconi R, Hefty R, Rinnab L, Schrader M, Schrader AJ. Nierentumore in der Schwangerschaft: Diagnostik und therapeutisches Management [Renal masses in pregnancy. Diagnostics and therapeutic management]. Urologe A 2011; 50(9):1064-1067.

Schütz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV, Schrader M. Inhibition of glycogen synthase kinase-3beta counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One 2011; 6(9):e25341.

Simon J, Finter F, Ignatius A, Meilinger M, Durselen L. Maximum tensile force of different suture techniques in reconstruction of the renal remnant after nephron-sparing surgery. Surg Endosc 2011; 25(2):503-507.

Steffens S, Grünwald V, Ringe KI, Seidel C, Eggers H, Schrader M, Wacker F, Kuczyk MA, Schrader AJ. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? Oncologist 2011; 16(11):1565-1571.

Steffens S, Schrader AJ, Blasig H, Vetter G, Eggers H, Trankenschuh W, Kuczyk MA, Serth J. Caveolin 1 protein expression in renal cell carcinoma predicts survival. BMC Urol 2011; 11:25.

Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kamat AM, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Dinney CP. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 2011; 107(6):898-904.

Waalkes S, Becker F, Schrader AJ, Janssen M, Wegener G, Merseburger AS, Schrader M, Hofmann R, Stockle M, Kuczyk MA. Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version? Eur Urol 2011; 59(2):258-263.

Waalkes S, Eggers H, Rustemeier J, Wegener G, Jentzmik F, Schrader M, Hofmann R, Kuczyk MA, Schrader AJ, Für das deutsche Netzwerk Nierenzelltumoren. Übergewicht ist ein günstiger Prognosefaktor für Patienten mit Nierenzellkarzinom [Overweight is an advantageous prognostic marker in patients with clear cell kidney cancer]. Urologe A 2011; 50(9):1118-1124.

Waalkes S, Roos FC, Eggers H, Schumacher S, Janssen M, Wegener G, Thuroff JW, Hofmann R, Schrader M, Kuczyk MA, Schrader AJ, deutsches Netzwerk Nierenzelltumoren. Inzidenz und Langzeitprognose des papillären Nierenzellkarzinoms: Ergebnisse einer retrospektiven Multicenterstudie [Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study]. Urologe A 2011; 50(9):1125-1129.

Waalkes S, Rott H, Herrmann TR, Wegener G, Kramer MW, Merseburger AS, Schrader M, Hofmann R, Kuczyk MA, Schrader AJ. Does male sex influence the prognosis of patients with renal cancer? Onkologie 2011; 34(1-2):24-28.

Wittig-Blaich SM, Kacprzyk LA, Eismann T, Bewerunge-Hudler M, Kruse P, Winkler E, Strauss WS, Hibst R, Steiner R, Schrader M, Mertens D, Sultmann H, Wittig R. Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells. Neoplasia 2011; 13(7):579-589.

Publikationen 2010

Azoitei N, Pusapati GV, Kleger A, Möller P, Küfer R, Genze F, Wagner M, van Lint J, Carmeliet P, Adler G, Seufferlein T. Protein kinase D2 is a crucial regulator of tumour cell-endothelial cell communication in gastrointestinal tumours. Gut 2010; 59(10):1316-1330.

Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, Shariat SF. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 2010; 57(2):300-309.

Greiner J, Küfer R, Reske SN, Martin V, Döhner H, Ringhoffer M. Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancer. Case Report Med 2010; 2010:395720.

Hautmann RE. Surgery illustrated - surgical atlas ileal neobladder. BJU Int 2010; 105(7):1024-1035.

Hautmann RE, de Petriconi RC, Volkmer BG. Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol 2010; 184(3):990-994.

Kassouf W, Hautmann RE, Bochner BH, Lerner SP, Colombo R, Zlotta A, Studer UE. A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution? Eur Urol 2010; 58(3):374-383.

Kastler S, Honold L, Luedeke M, Kuefer R, Moller P, Hoegel J, Vogel W, Maier C, Assum G. POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma. Prostate 2010; 70(6):666-674.

Nitzsche B, Gloesenkamp C, Schrader M, Ocker M, Preissner R, Lein M, Zakrzewicz A, Hoffmann B, Höpfner M. Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. Br J Cancer 2010; 103(1):18-28.

Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, Lotan Y, Isbarn H, Capitanio U, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Tilki D, Dinney CP, Lerner SP, Schoenberg M, Volkmer BG, Sagalowsky AI, Shariat SF. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol 2010; 183(6):2165-2170.

Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, Siddiqui J, Demichelis F, Moeller P, Bismar TA, Kuefer R, Fullen DR, Johnson TM, Greenson JK, Giordano TJ, Tan P, Tomlins SA, Varambally S, Rubin MA, Maher CA, Chinnaiyan AM. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010; 16(7):793-798.

Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F, Rickman DS, Rubin MA. ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology 2010; 75(4):762-767.

Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R, Schilling D, Fend F, Kristiansen G, Meyerson M, Rubin MA, Bubendorf L, Perner S. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010; 23(8):1061-1067.

Schrader M. Keimzelltumoren - ein Update [Germ cell cancer--an update]. Urologe A 2010; 49 Suppl 1166-168.

Schütz SV, Cronauer MV, Rinnab L. Inhibition of glycogen synthase kinase-3beta promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines. J Cell Biochem 2010; 109(6):1192-1200.

Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, Schoenberg MP, Kamat AM, Dinney CP, Lotan Y, Marberger MJ, Fradet Y. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 2010; 105(10):1402-1412.

Waalkes S, Atschekzei F, Kramer MW, Hennenlotter J, Vetter G, Becker JU, Stenzl A, Merseburger AS, Schrader AJ, Kuczyk MA, Serth J. Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer 2010; 10:503.

Waalkes S, Kramer M, Herrmann TR, Schrader AJ, Kuczyk MA, Merseburger AS. Present state of target therapy for disseminated renal cell carcinoma. Immunotherapy 2010; 2(3):393-398.

Waalkes S, Merseburger AS, Herrmann TR, Kramer MW, Wegener G, Rustemeier J, Hofmann R, Kuczyk MA, Schrader AJ. Urinary collecting system invasion is no independent prognostic factor in renal cell carcinoma. World J Urol 2010; 28(3):283-288.

Waalkes S, Merseburger AS, Kramer MW, Herrmann TR, Wegener G, Rustemeier J, Hofmann R, Schrader M, Kuczyk MA, Schrader AJ. Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer. Cancer Causes Control 2010; 21(11):1905-1910.

Wenz F, Martin T, Bohmer D, Martens S, Sedlmayer F, Wirth M, Miller K, Heidenreich A, Schrader M, Hinkelbein W, Wiegel T. The German S3 guideline prostate cancer: aspects for the radiation oncologist. Strahlenther Onkol 2010; 186(10):531-534.

Publikationen 2009

Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, LaFargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A, Svensson MA, Rickman DS, Urban A, Snyder M, Meyerson M, Lee C, Gerstein MB, Kuefer R, Rubin MA. Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer 2009; 48(4):366-380.

Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dork T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, Fitzgerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G, Easton DF. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009; 41(10):1116-1121.

Finter F, Rinnab L, Gust K, Küfer R. Palliative Systemtherapie des kastrationsresistenten Prostatakarzinoms: Aktuelle Entwicklungen [Palliative systemic therapy of castration-resistant prostate cancer: current developments]. Urologe A 2009; 48(11):1295-1301.

Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L, Rubin MA, Greiner J, Schmitt M, Kuefer R, Ringhoffer M. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia 2009; 11(9):956-963.

Hautmann RE. The oncologic results of laparoscopic radical cystectomy are not (yet) equivalent to open cystectomy. Curr Opin Urol 2009; 19(5):522-526.

Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol 2009; 27(3):347-351.

Hautmann RE, de Petriconi R, Volkmer BG. Neobladder formation after pelvic irradiation. World J Urol 2009; 27(1):57-62.

Hautmann RE. Editorial comment on: Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009; 55(1):174.

Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer. Cancer Res 2009; 69(2):640-646.

Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M. Metastasenchirurgie in kurativer Absicht beim Urothekarzinom [Complete resection of urothelial cancer metastases with curative intent]. Urologe A 2009; 48(2):143-150.

Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol 2009; 55(6):1293-1299.

Luedeke M, Linnert CM, Hofer MD, Surowy HM, Rinckleb AE, Hoegel J, Kuefer R, Rubin MA, Vogel W, Maier C. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes. Cancer Epidemiol Biomarkers Prev 2009; 18(11):3030-3035.

Petschl S, Finter F, Gust K, Volkmer BG. Greenlightlaserbehandlung der BPS: Dilemma der Vergütung im DRG-System [GreenLight laser therapy for benign prostatic hyperplasia: dilemma of reimbursement in the DRG system]. Urologe A 2009; 48(2):177-182.

Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la TA, Kuefer R, Tewari AK, Demichelis F, Chee MS, Gerstein MB, Rubin MA. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009; 11(8):804-811.

Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la TA, Kuefer R, Tewari AK, Setlur SR, Demichelis F, Rubin MA. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res 2009; 69(7):2734-2738.

Ringhoffer M, Rinnab L, Küfer R, Greiner J. Systemtherapie des metastasierten Nierenzellkarzinoms: Von der Vielzahl der Möglichkeiten zur therapeutischen Strategie [Systemic therapy of metastatic renal cell carcinoma: from many options to the therapeutic strategy]. Urologe A 2009; 48(11):1308-1317.

Rinnab L, Ringhoffer M, Mayer-Steinacker R, Hautmann RE, Simon J. Prävention, Früherkennung und Behandlung von Zytostatikaparavasaten [Prevention, early diagnosis and treatment of chemoextravasation. Practical management in the uro-oncological practice]. Urologe A 2009; 48(11):1283-90, 1292.

Rinnab L, Gust K, Hautmann RE, Küfer R. Testosteronsubstitution und Prostatakarzinom: Eine Standortbestimmung 67 Jahre nch dem Huggins-Mythos [Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth]. Urologe A 2009; 48(5):516-522.

Rinnab L, Simon J, Hautmann RE, Cronauer MV, Hohl K, Buck AK, Reske SN, Mottaghy FM. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009; 27(5):619-625.

Rinnab L, Küfer R. Aktuelle Aspekte und Therapiestrategien in der medikamentösen ambulanten uroonkologischen Therapie [Current aspects and medication therapy strategies for out-patient uro-oncological therapy]. Urologe A 2009; 48(11):1261-1262.

Schnöller T, Küfer R, Eismann T, Rinnab L. Komplementärmedizin in der Onkologie [Complementary medicine in oncology]. Urologe A 2009; 48(11):1302, 1304-1302, 1307.

Simon J, Finter F, Schnöller T, Hautmann R, Rinnab L. Intravesikale Therapie beim nicht muskelinvasiven Urothelkarzinom der Harnblase [Intravesical therapy in non-muscle-invasive bladder cancer: indications and practical considerations]. Urologe A 2009; 48(11):1263-8, 1270.

Simon J, Bartsch G, Jr., Rinnab L, Hautmann RE, Volkmer BG. Transrectal ultrasound as diagnostic tool for the detection of local recurrence following cystectomy and urinary diversion. Urol Int 2009; 82(1):12-16.

Stein JP, Hautmann RE, Penson D, Skinner DG. Prostate-sparing cystectomy: a review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer. Urol Oncol 2009; 27(5):466-472.

Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S, Hofer MD, Kuefer R, Chinnaiyan A, Rubin MA, Pienta KJ, Robins DM. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009; 69(10):4434-4442.

Vickers AJ, Cronin AM, Kattan MW, Gonen M, Scardino PT, Milowsky MI, Dalbagni G, Bochner BH. Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. Cancer 2009; 115(23):5460-5469.

Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Moller P, Gschwend JE, Simmet T, Debatin KM, Fulda S. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009; 69(6):2425-2434.

Volkmer BG, Kuefer R, Bartsch GC, Jr., Gust K, Hautmann RE. Oncological followup after radical cystectomy for bladder cancer-is there any benefit? J Urol 2009; 181(4):1587-1593.

Volkmer BG, Schnoeller T, Kuefer R, Gust K, Finter F, Hautmann RE. Upper urinary tract recurrence after radical cystectomy for bladder cancer--who is at risk? J Urol 2009; 182(6):2632-2637.

Wenke A, Franz D, Puhse G, Volkmer B, Roeder N. [Adjustment of the German DRG system in 2009]. Urologe A 2009; 48(7):774-784.

Youssef RF, Mitra AP, Bartsch G, Jr., Jones PA, Skinner DG, Cote RJ. Molecular targets and targeted therapies in bladder cancer management. World J Urol 2009; 27(1):9-20.

Publikationen

2015

2014

2013

2012

2011

2010

2009 

gepunktete hellblaue Linie 176px breit
gepunktete blaue Linie 1000px breit